|
1
|
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
|
N Engl J Med
|
2015
|
18.66
|
|
2
|
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
|
Lancet
|
2011
|
13.10
|
|
3
|
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.
|
N Engl J Med
|
2013
|
7.54
|
|
4
|
Everolimus in patients with autosomal dominant polycystic kidney disease.
|
N Engl J Med
|
2010
|
5.50
|
|
5
|
Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial.
|
JAMA
|
2012
|
5.27
|
|
6
|
Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study.
|
Lancet
|
2003
|
3.70
|
|
7
|
Review on uremic toxins: classification, concentration, and interindividual variability.
|
Kidney Int
|
2003
|
3.54
|
|
8
|
EBPG on Vascular Access.
|
Nephrol Dial Transplant
|
2007
|
3.26
|
|
9
|
EBPG guideline on nutrition.
|
Nephrol Dial Transplant
|
2007
|
2.68
|
|
10
|
Vitamin D status and clinical outcomes in incident dialysis patients: results from the NECOSAD study.
|
Nephrol Dial Transplant
|
2010
|
2.64
|
|
11
|
Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3.
|
Mol Genet Metab
|
2008
|
2.60
|
|
12
|
Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry.
|
Mol Genet Metab
|
2007
|
2.51
|
|
13
|
Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis.
|
Ann Intern Med
|
2012
|
2.51
|
|
14
|
Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease.
|
Am Heart J
|
2012
|
2.42
|
|
15
|
Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study.
|
Circulation
|
2003
|
2.22
|
|
16
|
Expert opinion on temporary treatment recommendations for Fabry disease during the shortage of enzyme replacement therapy (ERT).
|
Mol Genet Metab
|
2010
|
2.13
|
|
17
|
Oxidative stress in end-stage renal disease: an emerging threat to patient outcome.
|
Nephrol Dial Transplant
|
2003
|
2.10
|
|
18
|
Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment.
|
Circulation
|
2009
|
2.07
|
|
19
|
Predicting mortality in incident dialysis patients: an analysis of the United Kingdom Renal Registry.
|
Am J Kidney Dis
|
2011
|
2.01
|
|
20
|
EBPG guideline on dialysis strategies.
|
Nephrol Dial Transplant
|
2007
|
1.90
|
|
21
|
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia.
|
Am J Cardiol
|
2008
|
1.88
|
|
22
|
Fabry disease: guidelines for the evaluation and management of multi-organ system involvement.
|
Genet Med
|
2006
|
1.87
|
|
23
|
Etiology of the protein-energy wasting syndrome in chronic kidney disease: a consensus statement from the International Society of Renal Nutrition and Metabolism (ISRNM).
|
J Ren Nutr
|
2013
|
1.85
|
|
24
|
Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patients.
|
Eur Heart J
|
2010
|
1.72
|
|
25
|
Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy.
|
Am J Cardiol
|
2006
|
1.71
|
|
26
|
Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis.
|
PLoS Genet
|
2012
|
1.69
|
|
27
|
Association of eGFR-Related Loci Identified by GWAS with Incident CKD and ESRD.
|
PLoS Genet
|
2011
|
1.68
|
|
28
|
EBPG guideline on haemodynamic instability.
|
Nephrol Dial Transplant
|
2007
|
1.65
|
|
29
|
The challenge of sudden death in dialysis patients.
|
Clin J Am Soc Nephrol
|
2008
|
1.52
|
|
30
|
Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy.
|
Nephrol Dial Transplant
|
2008
|
1.46
|
|
31
|
Apolipoprotein E genotype predicts cardiovascular endpoints in dialysis patients with type 2 diabetes mellitus.
|
Atherosclerosis
|
2009
|
1.45
|
|
32
|
Tei index in fabry disease.
|
J Am Soc Echocardiogr
|
2011
|
1.44
|
|
33
|
OPPORTUNITY™: a large-scale randomized clinical trial of growth hormone in hemodialysis patients.
|
Nephrol Dial Transplant
|
2011
|
1.44
|
|
34
|
Impact of oxidized low density lipoprotein on vascular cells.
|
Atherosclerosis
|
2005
|
1.43
|
|
35
|
The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: a pooled analysis of double-blind, randomized trials.
|
Int J Cardiol
|
2006
|
1.43
|
|
36
|
Endothelial progenitor cells in patients on extracorporeal maintenance dialysis therapy.
|
Nephrol Dial Transplant
|
2010
|
1.41
|
|
37
|
Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy.
|
Biochim Biophys Acta
|
2010
|
1.35
|
|
38
|
Reverse epidemiology in systolic and nonsystolic heart failure: cumulative prognostic benefit of classical cardiovascular risk factors.
|
Circ Heart Fail
|
2009
|
1.35
|
|
39
|
Inflammation and outcome in end-stage renal failure: does female gender constitute a survival advantage?
|
Kidney Int
|
2002
|
1.33
|
|
40
|
The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease.
|
Eur Heart J
|
2005
|
1.32
|
|
41
|
Understanding competing risks: a simulation point of view.
|
BMC Med Res Methodol
|
2011
|
1.31
|
|
42
|
Identification of a new tumor suppressor gene located at chromosome 8p21.3-22.
|
FASEB J
|
2003
|
1.31
|
|
43
|
Prevention and treatment of protein energy wasting in chronic kidney disease patients: a consensus statement by the International Society of Renal Nutrition and Metabolism.
|
Kidney Int
|
2013
|
1.31
|
|
44
|
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient.
|
Diab Vasc Dis Res
|
2008
|
1.27
|
|
45
|
Factors influencing the decision to start renal replacement therapy: results of a survey among European nephrologists.
|
Am J Kidney Dis
|
2012
|
1.26
|
|
46
|
Cross-talk between the kidney and the cardiovascular system.
|
J Am Soc Nephrol
|
2006
|
1.25
|
|
47
|
Carbamylation of serum albumin as a risk factor for mortality in patients with kidney failure.
|
Sci Transl Med
|
2013
|
1.25
|
|
48
|
Native C-reactive protein increases whereas modified C-reactive protein reduces atherosclerosis in apolipoprotein E-knockout mice.
|
Circulation
|
2005
|
1.24
|
|
49
|
Timing and outcome of renal replacement therapy in patients with congenital malformations of the kidney and urinary tract.
|
Clin J Am Soc Nephrol
|
2012
|
1.24
|
|
50
|
Copeptin levels associate with cardiovascular events in patients with ESRD and type 2 diabetes mellitus.
|
J Am Soc Nephrol
|
2011
|
1.23
|
|
51
|
Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON).
|
Am J Nephrol
|
2013
|
1.23
|
|
52
|
Effects of comorbid and demographic factors on dialysis modality choice and related patient survival in Europe.
|
Nephrol Dial Transplant
|
2011
|
1.23
|
|
53
|
Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation.
|
Nephrol Dial Transplant
|
2011
|
1.23
|
|
54
|
End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry.
|
Nephrol Dial Transplant
|
2009
|
1.22
|
|
55
|
Residual macrovascular risk in 2013: what have we learned?
|
Cardiovasc Diabetol
|
2014
|
1.20
|
|
56
|
Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis.
|
Clin J Am Soc Nephrol
|
2011
|
1.19
|
|
57
|
Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults.
|
Nat Clin Pract Nephrol
|
2008
|
1.19
|
|
58
|
Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case-control study in 13 countries.
|
Circulation
|
2013
|
1.13
|
|
59
|
Bone alkaline phosphatase and mortality in dialysis patients.
|
Clin J Am Soc Nephrol
|
2011
|
1.13
|
|
60
|
Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™).
|
Cardiovasc Diabetol
|
2014
|
1.12
|
|
61
|
Advanced glycation end products and mortality in hemodialysis patients.
|
Kidney Int
|
2002
|
1.12
|
|
62
|
Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline.
|
Ann Intern Med
|
2014
|
1.11
|
|
63
|
Glycemic control and cardiovascular events in diabetic hemodialysis patients.
|
Circulation
|
2009
|
1.10
|
|
64
|
The 2008 ERA-EDTA Registry Annual Report-a précis.
|
NDT Plus
|
2010
|
1.10
|
|
65
|
The German Chronic Kidney Disease (GCKD) study: design and methods.
|
Nephrol Dial Transplant
|
2011
|
1.09
|
|
66
|
Lack of endothelial nitric oxide synthase promotes endothelin-induced hypertension: lessons from endothelin-1 transgenic/endothelial nitric oxide synthase knockout mice.
|
J Am Soc Nephrol
|
2007
|
1.07
|
|
67
|
Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial.
|
Nephrol Dial Transplant
|
2013
|
1.07
|
|
68
|
Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch.
|
J Am Soc Nephrol
|
2014
|
1.07
|
|
69
|
Electrocardiography and outcome in patients with diabetes mellitus on maintenance hemodialysis.
|
Clin J Am Soc Nephrol
|
2009
|
1.06
|
|
70
|
Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation?
|
Kidney Int
|
2003
|
1.06
|
|
71
|
Novel insights into uremic vascular calcification: role of matrix Gla protein and alpha-2-Heremans Schmid glycoprotein/fetuin.
|
Blood Purif
|
2002
|
1.06
|
|
72
|
Change in N-terminal-pro-B-type-natriuretic-peptide and the risk of sudden death, stroke, myocardial infarction, and all-cause mortality in diabetic dialysis patients.
|
Eur Heart J
|
2008
|
1.05
|
|
73
|
Homoarginine, cardiovascular risk, and mortality.
|
Circulation
|
2010
|
1.04
|
|
74
|
National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events.
|
Kidney Int
|
2010
|
1.04
|
|
75
|
Statins, inflammation and kidney disease.
|
Nat Rev Nephrol
|
2011
|
1.04
|
|
76
|
The association between parathyroid hormone and mortality in dialysis patients is modified by wasting.
|
Nephrol Dial Transplant
|
2009
|
1.04
|
|
77
|
Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry disease.
|
Circ Cardiovasc Genet
|
2014
|
1.03
|
|
78
|
Changes in adiponectin and the risk of sudden death, stroke, myocardial infarction, and mortality in hemodialysis patients.
|
Kidney Int
|
2009
|
1.03
|
|
79
|
Dialyzer membrane characteristics and outcome of patients with type 2 diabetes on maintenance hemodialysis.
|
Am J Kidney Dis
|
2007
|
1.02
|
|
80
|
Deficiencies of calcium-regulatory proteins in dialysis patients: a novel concept of cardiovascular calcification in uremia.
|
Kidney Int Suppl
|
2003
|
1.01
|
|
81
|
Down-regulation of MTUS1 in human colon tumors.
|
Oncol Rep
|
2010
|
1.01
|
|
82
|
Myeloperoxidase serves as a marker of oxidative stress during single haemodialysis session using two different biocompatible dialysis membranes.
|
Nephrol Dial Transplant
|
2005
|
1.00
|
|
83
|
Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment.
|
JACC Cardiovasc Imaging
|
2011
|
1.00
|
|
84
|
Sample sizes for clinical trials with time-to-event endpoints and competing risks.
|
Contemp Clin Trials
|
2005
|
0.98
|
|
85
|
Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis.
|
Kidney Int
|
2008
|
0.98
|
|
86
|
The issue of studying the effect of interventions in renal replacement therapy -- to what extent may we be deceived by selection and competing risk?
|
Nephrol Dial Transplant
|
2010
|
0.97
|
|
87
|
The importance of diabetic nephropathy in current nephrological practice.
|
Nephrol Dial Transplant
|
2003
|
0.97
|
|
88
|
Tubular staining of modified C-reactive protein in diabetic chronic kidney disease.
|
Nephrol Dial Transplant
|
2003
|
0.97
|
|
89
|
Endogenous erythropoietin and the association with inflammation and mortality in diabetic chronic kidney disease.
|
Clin J Am Soc Nephrol
|
2011
|
0.96
|
|
90
|
Homoarginine, heart failure, and sudden cardiac death in haemodialysis patients.
|
Eur J Heart Fail
|
2011
|
0.96
|
|
91
|
Nephropathy in Fabry disease: the importance of early diagnosis and testing in high-risk populations.
|
Nephrol Dial Transplant
|
2009
|
0.96
|
|
92
|
Native C-reactive protein induces endothelial dysfunction in ApoE-/- mice: implications for iNOS and reactive oxygen species.
|
Atherosclerosis
|
2007
|
0.96
|
|
93
|
Wasting and sudden cardiac death in hemodialysis patients: a post hoc analysis of 4D (Die Deutsche Diabetes Dialyse Studie).
|
Am J Kidney Dis
|
2011
|
0.96
|
|
94
|
Fibrosis: a key feature of Fabry disease with potential therapeutic implications.
|
Orphanet J Rare Dis
|
2013
|
0.95
|
|
95
|
Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy.
|
J Nephrol
|
2008
|
0.95
|
|
96
|
Minimizing risk of nephrogenic systemic fibrosis in cardiovascular magnetic resonance.
|
J Cardiovasc Magn Reson
|
2012
|
0.95
|
|
97
|
A validated disease severity scoring system for Fabry disease.
|
Mol Genet Metab
|
2009
|
0.95
|
|
98
|
Protein-bound uraemic toxin removal in haemodialysis and post-dilution haemodiafiltration.
|
Nephrol Dial Transplant
|
2009
|
0.95
|
|
99
|
Implementation of an in vitro model system for investigation of reperfusion damage after renal ischemia.
|
Cell Physiol Biochem
|
2009
|
0.94
|
|
100
|
An assessment of statin safety by nephrologists.
|
Am J Cardiol
|
2006
|
0.93
|
|
101
|
Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
|
Nephrol Dial Transplant
|
2008
|
0.92
|
|
102
|
The Fabry cardiomyopathy: models for the cardiologist.
|
Annu Rev Med
|
2011
|
0.92
|
|
103
|
Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice.
|
Nephrol Dial Transplant
|
2012
|
0.91
|
|
104
|
Department-related tasks and organ-targeted therapy in Fabry disease: an interdisciplinary challenge.
|
Am J Med
|
2010
|
0.90
|
|
105
|
L-arginine deficiency and supplementation in experimental acute renal failure and in human kidney transplantation.
|
Kidney Int
|
2002
|
0.90
|
|
106
|
Low homoarginine concentration is a novel risk factor for heart disease.
|
Heart
|
2011
|
0.90
|
|
107
|
Association of body mass index with decline in residual kidney function after initiation of dialysis.
|
Am J Kidney Dis
|
2009
|
0.90
|
|
108
|
L-Arginine counteracts nitric oxide deficiency and improves the recovery phase of ischemic acute renal failure in rats.
|
Kidney Int
|
2003
|
0.90
|
|
109
|
Conservative care in Europe--nephrologists' experience with the decision not to start renal replacement therapy.
|
Nephrol Dial Transplant
|
2013
|
0.89
|
|
110
|
Lipid changes and statins in chronic renal insufficiency.
|
J Am Soc Nephrol
|
2006
|
0.89
|
|
111
|
Lyso-Gb3 Indicates that the Alpha-Galactosidase A Mutation D313Y is not Clinically Relevant for Fabry Disease.
|
JIMD Rep
|
2012
|
0.89
|
|
112
|
Enzyme replacement therapy in Fabry disease: clinical implications.
|
Curr Opin Nephrol Hypertens
|
2003
|
0.88
|
|
113
|
C-reactive protein: a family of proteins to regulate cardiovascular function.
|
Am J Kidney Dis
|
2006
|
0.88
|
|
114
|
Two-dimensional speckle tracking as a non-invasive tool for identification of myocardial fibrosis in Fabry disease.
|
Eur Heart J
|
2013
|
0.88
|
|
115
|
Impaired small fiber conduction in patients with Fabry disease: a neurophysiological case-control study.
|
BMC Neurol
|
2013
|
0.87
|
|
116
|
Lipid abnormalities and cardiovascular risk in renal disease.
|
J Am Soc Nephrol
|
2008
|
0.87
|
|
117
|
A new echocardiographic approach for the detection of non-ischaemic fibrosis in hypertrophic myocardium.
|
Eur Heart J
|
2007
|
0.87
|
|
118
|
Vitamin D receptor activation and left ventricular hypertrophy in advanced kidney disease.
|
Am J Nephrol
|
2011
|
0.87
|
|
119
|
The use of group sequential, information-based sample size re-estimation in the design of the PRIMO study of chronic kidney disease.
|
Clin Trials
|
2011
|
0.86
|
|
120
|
Heart valve involvement in Fabry cardiomyopathy.
|
Ultrasound Med Biol
|
2008
|
0.86
|
|
121
|
Interdisciplinary approach towards female patients with Fabry disease.
|
Eur J Clin Invest
|
2011
|
0.86
|
|
122
|
Homoarginine and progression of chronic kidney disease: results from the Mild to Moderate Kidney Disease Study.
|
PLoS One
|
2013
|
0.86
|
|
123
|
Changes in parathyroid hormone, body mass index and the association with mortality in dialysis patients.
|
Nephrol Dial Transplant
|
2010
|
0.86
|
|
124
|
Impact of mycophenolate mofetil on wound complications and lymphoceles after kidney transplantation.
|
Kidney Blood Press Res
|
2010
|
0.85
|
|
125
|
Diabetic nephropathy: an inherited disease or just a diabetic complication?
|
Kidney Blood Press Res
|
2003
|
0.85
|
|
126
|
Hidden population substructures in an apparently homogeneous population bias association studies.
|
Eur J Hum Genet
|
2006
|
0.85
|
|
127
|
Transmission of oxLDL-derived lipid peroxide radicals into membranes of vascular cells is the main inducer of oxLDL-mediated oxidative stress.
|
Atherosclerosis
|
2007
|
0.84
|
|
128
|
Optimal treatment of renal anaemia (OPTA): improving the efficacy and efficiency of renal anaemia therapy in haemodialysis patients receiving intravenous epoetin.
|
Nephrol Dial Transplant
|
2005
|
0.84
|
|
129
|
Fabry disease: diagnosis and treatment.
|
Kidney Int Suppl
|
2003
|
0.83
|
|
130
|
Bisphenol A in chronic kidney disease.
|
Artif Organs
|
2012
|
0.83
|
|
131
|
Case Report: Atheroembolic renal disease in a 72-year-old patient through coronary intervention after myocardial infarction.
|
Hemodial Int
|
2008
|
0.83
|
|
132
|
The Fabry cardiomyopathy - diagnostic approach and current treatment.
|
Curr Pharm Des
|
2015
|
0.82
|
|
133
|
The role of EUTox in uremic toxin research.
|
Semin Dial
|
2009
|
0.82
|
|
134
|
Genome-wide association study identifies 3 genomic loci significantly associated with serum levels of homoarginine: the AtheroRemo Consortium.
|
Circ Cardiovasc Genet
|
2013
|
0.82
|
|
135
|
Endothelin B receptor-deficient mice develop endothelial dysfunction independently of salt loading.
|
J Hypertens
|
2005
|
0.82
|
|
136
|
Inflammation in uremic patients: what is the link?
|
Kidney Blood Press Res
|
2003
|
0.82
|
|
137
|
Enzyme replacement therapy for Fabry's disease.
|
Lancet
|
2010
|
0.82
|
|
138
|
Oxidized LDL and its compound lysophosphatidylcholine potentiate AngII-induced vasoconstriction by stimulation of RhoA.
|
J Am Soc Nephrol
|
2003
|
0.82
|
|
139
|
Aldosterone and cortisol affect the risk of sudden cardiac death in haemodialysis patients.
|
Eur Heart J
|
2012
|
0.81
|
|
140
|
Cardiac energy metabolism is disturbed in Fabry disease and improves with enzyme replacement therapy using recombinant human galactosidase A.
|
Eur J Heart Fail
|
2010
|
0.81
|
|
141
|
Predicting erythropoietin resistance in hemodialysis patients with type 2 diabetes.
|
BMC Nephrol
|
2013
|
0.81
|
|
142
|
Transthyretin predicts cardiovascular outcome in hemodialysis patients with type 2 diabetes.
|
Diabetes Care
|
2012
|
0.81
|
|
143
|
Monomeric C-reactive protein decreases acetylated LDL uptake in human endothelial cells.
|
Clin Chem
|
2009
|
0.81
|
|
144
|
Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus.
|
Am J Kidney Dis
|
2009
|
0.81
|
|
145
|
Low serum homoarginine is a novel risk factor for fatal strokes in patients undergoing coronary angiography.
|
Stroke
|
2011
|
0.81
|
|
146
|
The effect of high-flux hemodialysis on hemoglobin concentrations in patients with CKD: results of the MINOXIS study.
|
Clin J Am Soc Nephrol
|
2011
|
0.81
|
|
147
|
Sunrise of statins after AURORA and 4D?
|
J Am Soc Nephrol
|
2011
|
0.81
|
|
148
|
Rationale and design of the Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease Study (MiREnDa).
|
Nephrol Dial Transplant
|
2013
|
0.80
|
|
149
|
Endothelial dysfunction and inflammation: what is the link?
|
Kidney Int Suppl
|
2003
|
0.80
|
|
150
|
Increased symmetrical dimethylarginine in ischemic acute kidney injury as a causative factor of renal L-arginine deficiency.
|
Transl Res
|
2013
|
0.80
|
|
151
|
Advanced renal insufficiency in a 34-year-old man with Lowe syndrome.
|
Am J Kidney Dis
|
2004
|
0.80
|
|
152
|
The right ventricle in Fabry disease: natural history and impact of enzyme replacement therapy.
|
Heart
|
2010
|
0.80
|
|
153
|
What guidelines should or should not be: implications for guideline production.
|
Nephrol Dial Transplant
|
2013
|
0.80
|
|
154
|
Dyslipidemia, inflammation and dialysis outcomes: what we know now.
|
Curr Opin Nephrol Hypertens
|
2006
|
0.80
|
|
155
|
Low plasma α-tocopherol concentrations and adverse clinical outcomes in diabetic hemodialysis patients.
|
Clin J Am Soc Nephrol
|
2013
|
0.80
|
|
156
|
Study design of DIACORE (DIAbetes COhoRtE) - a cohort study of patients with diabetes mellitus type 2.
|
BMC Med Genet
|
2013
|
0.80
|
|
157
|
A new synthetic dialyzer with advanced permselectivity for enhanced low-molecular weight protein removal.
|
Artif Organs
|
2008
|
0.79
|
|
158
|
Antibodies to platelet factor 4-heparin complex and outcome in hemodialysis patients with diabetes.
|
Clin J Am Soc Nephrol
|
2010
|
0.79
|
|
159
|
Cross-sectional baseline analysis of electrocardiography in a large cohort of patients with untreated Fabry disease.
|
J Inherit Metab Dis
|
2012
|
0.79
|
|
160
|
L-Arginine does not affect renal morphology and cell survival in ischemic acute renal failure in rats.
|
Nephron Physiol
|
2005
|
0.79
|
|
161
|
Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and cardiovascular risk and efficacy of atorvastatin among subjects with diabetes on dialysis: the 4D study.
|
Atherosclerosis
|
2011
|
0.79
|
|
162
|
Are glucokinase mutations associated with low triglycerides?
|
Clin Chem
|
2005
|
0.79
|
|
163
|
Prominent papillary muscles in Fabry disease: a diagnostic marker?
|
Ultrasound Med Biol
|
2010
|
0.79
|
|
164
|
Impact of vitamin A on clinical outcomes in haemodialysis patients.
|
Nephrol Dial Transplant
|
2011
|
0.79
|
|
165
|
Lipoprotein-associated phospholipase A2 and outcome in patients with type 2 diabetes on haemodialysis.
|
Eur J Clin Invest
|
2011
|
0.78
|
|
166
|
Association between pre-transplant dialysis modality and patient and graft survival after kidney transplantation.
|
Nephrol Dial Transplant
|
2012
|
0.78
|
|
167
|
Rosiglitazone affects nitric oxide synthases and improves renal outcome in a rat model of severe ischemia/reperfusion injury.
|
PPAR Res
|
2012
|
0.78
|
|
168
|
OPPORTUNITY: a randomized clinical trial of growth hormone on outcome in hemodialysis patients.
|
Clin J Am Soc Nephrol
|
2008
|
0.78
|
|
169
|
Longitudinal assessments of erythropoietin-stimulating agent responsiveness and the association with specific clinical outcomes in dialysis patients.
|
Nephron Clin Pract
|
2014
|
0.77
|
|
170
|
At which stage of chronic kidney disease should dyslipidemia be treated?
|
Nat Clin Pract Nephrol
|
2006
|
0.77
|
|
171
|
Effects of pravastatin treatment on blood pressure regulation after renal transplantation.
|
Kidney Blood Press Res
|
2006
|
0.77
|
|
172
|
Progression of Fabry cardiomyopathy.
|
Clin Ther
|
2007
|
0.77
|
|
173
|
Enzyme replacement therapy for Fabry disease: proving the clinical benefit.
|
Nephrol Dial Transplant
|
2003
|
0.77
|
|
174
|
Clearance of drugs for multiple myeloma therapy during in vitro high-cutoff hemodialysis.
|
Artif Organs
|
2014
|
0.77
|
|
175
|
Homoarginine, kidney function and cardiovascular mortality risk.
|
Nephrol Dial Transplant
|
2014
|
0.77
|
|
176
|
Vasopeptidase inhibition normalizes blood pressure and restores endothelial function in renovascular hypertension.
|
Kidney Blood Press Res
|
2006
|
0.77
|
|
177
|
Pathologic endothelial response and impaired function of circulating angiogenic cells in patients with Fabry disease.
|
Basic Res Cardiol
|
2012
|
0.77
|
|
178
|
Disease classification: a pitfall of the ERA/EDTA registry?
|
Nephrol Dial Transplant
|
2010
|
0.77
|
|
179
|
Genetic aspects of diabetic nephropathy.
|
Kidney Int Suppl
|
2003
|
0.77
|
|
180
|
Vasopeptidase inhibition: a new treatment approach for endothelial dysfunction.
|
Kidney Int Suppl
|
2003
|
0.77
|
|
181
|
Microtubule associated tumor suppressor 1 deficient mice develop spontaneous heart hypertrophy and SLE-like lymphoproliferative disease.
|
Int J Oncol
|
2011
|
0.77
|
|
182
|
Initial use of once-monthly administration of C.E.R.A. is effective and safe in correcting renal anemia in non-dialysis patients: the MERCUR trial.
|
Clin Nephrol
|
2012
|
0.77
|
|
183
|
Fabry nephropathy and the case for adjunctive renal therapy.
|
J Am Soc Nephrol
|
2007
|
0.76
|
|
184
|
Long-Term Evaluation of Colestilan in Chronic Kidney Disease Stage 5 Dialysis Patients with Hyperphosphataemia.
|
Blood Purif
|
2015
|
0.76
|
|
185
|
Efficacy and safety of preemptive anti-CMV therapy with valganciclovir after kidney transplantation.
|
Clin Transplant
|
2007
|
0.76
|
|
186
|
Homoarginine and Clinical Outcomes in Renal Transplant Recipients: Results From the Assessment of Lescol in Renal Transplantation Study.
|
Transplantation
|
2015
|
0.76
|
|
187
|
Lessons learnt from the 4D trial.
|
Nephrol Ther
|
2006
|
0.76
|
|
188
|
MR-based analysis of regional cardiac function in relation to cellular integrity in Fabry disease.
|
Int J Cardiol
|
2011
|
0.76
|
|
189
|
Kidney function as an underestimated factor for reduced health related quality of life in patients with Fabry disease.
|
BMC Nephrol
|
2014
|
0.76
|
|
190
|
Beta(2)-microglobulin removal by extracorporeal renal replacement therapies.
|
Biochim Biophys Acta
|
2005
|
0.76
|
|
191
|
Long Term Treatment with Enzyme Replacement Therapy in Patients with Fabry Disease.
|
Nephron
|
2016
|
0.76
|
|
192
|
Potential role of vitamin D deficiency on Fabry cardiomyopathy.
|
J Inherit Metab Dis
|
2013
|
0.75
|
|
193
|
New AHA and ACC guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk.
|
Wien Klin Wochenschr
|
2014
|
0.75
|
|
194
|
Diabetes: Should we use fibrates in patients with diabetes and mild CKD?
|
Nat Rev Nephrol
|
2012
|
0.75
|
|
195
|
The effects of colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphataemia: a 1-year prospective randomized study.
|
Nephrol Dial Transplant
|
2013
|
0.75
|
|
196
|
Hypertension after kidney transplantation: still a SECRET?
|
Nephrol Dial Transplant
|
2009
|
0.75
|
|
197
|
Introduction to Focus on Fabry nephropathy: biomarkers, progression, and disease severity.
|
Clin J Am Soc Nephrol
|
2009
|
0.75
|
|
198
|
A distinct urinary biomarker pattern characteristic of female Fabry patients that mirrors response to enzyme replacement therapy.
|
PLoS One
|
2011
|
0.75
|
|
199
|
Statins and aspirin in chronic kidney disease: what does the UK-HARP-I trial tell us?
|
Am J Kidney Dis
|
2005
|
0.75
|
|
200
|
Copeptin: a marker for ADPKD progression?
|
Nephrol Dial Transplant
|
2012
|
0.75
|
|
201
|
Statin use prolongs patient survival after renal transplantation.
|
J Am Soc Nephrol
|
2008
|
0.75
|
|
202
|
Correction: Heart Failure in a Cohort of Patients with Chronic Kidney Disease: The GCKD Study.
|
PLoS One
|
2015
|
0.75
|
|
203
|
Statins: do we definitely know whether they are completely inefficacious in ESRD?
|
Kidney Int
|
2010
|
0.75
|
|
204
|
Long interdialytic interval and mortality.
|
N Engl J Med
|
2011
|
0.75
|
|
205
|
Statin effects in CKD: is there a "point of no return"?
|
Am J Kidney Dis
|
2009
|
0.75
|
|
206
|
Should we reconsider the advanced glycation end product issue in hemodialysis patients?
|
Am J Kidney Dis
|
2006
|
0.75
|
|
207
|
C-reactive protein risk prediction: adding cardiac hypertrophy to the list.
|
Am J Kidney Dis
|
2002
|
0.75
|
|
208
|
A new team for the Journal of Renal Nutrition for the next decade/2.
|
J Ren Nutr
|
2011
|
0.75
|
|
209
|
Methodology used in studies reporting chronic kidney disease prevalence: a systematic literature review.
|
Nephrol Dial Transplant
|
2016
|
0.75
|
|
210
|
Conservative treatment of the uremic syndrome.
|
Semin Dial
|
2009
|
0.75
|
|
211
|
Chronic renal failure and its complications.
|
Kidney Blood Press Res
|
2011
|
0.75
|
|
212
|
Ischemic acute renal failure in the rat: effects of L-arginine and superoxide dismutase on renal function.
|
J Nephrol
|
2008
|
0.75
|
|
213
|
The ISN Clinical Practice Guidelines Committee.
|
Nat Clin Pract Nephrol
|
2008
|
0.75
|
|
214
|
Effects of a polyelectrolyte additive on the selective dialysis membrane permeability for low-molecular-weight proteins.
|
Nephrol Dial Transplant
|
2006
|
0.75
|
|
215
|
Umbilical angiectases as the sole clinical sign of Fabry disease in a 9-year-old boy.
|
Eur J Pediatr
|
2005
|
0.75
|
|
216
|
[Division-related function and organ-related therapy in Fabry's disease. An interdisciplinary challenge].
|
Med Klin (Munich)
|
2009
|
0.75
|
|
217
|
Progressive anorexia and chronic ascites after termination of CAPD.
|
Nephrol Dial Transplant
|
2002
|
0.75
|
|
218
|
KDIGO clinical practice guidelines on hepatitis C in chronic kidney disease acknowledged by ISN.
|
Nat Clin Pract Nephrol
|
2008
|
0.75
|
|
219
|
[Epidemiology of Chronic Kidney Disease - Ever More Patients?]
|
Dtsch Med Wochenschr
|
2017
|
0.75
|
|
220
|
[Conflicts in the threshold for renal failure: when must the patient receive dialysis? (interview by Dr. Jochen Aumiler)].
|
MMW Fortschr Med
|
2012
|
0.75
|
|
221
|
Randomized, Double-Blind, Placebo-Controlled, Withdrawal Study of Colestilan after Dose Titration in Chronic Kidney Disease Dialysis Patients with Hyperphosphatemia.
|
Nephron
|
2015
|
0.75
|
|
222
|
[Females with Fabry's disease - an interdisciplinary diagnostic and therapeutic challenge].
|
Med Klin (Munich)
|
2010
|
0.75
|
|
223
|
Foreword. The 8th Annual European Round Table on Fabry Disease.
|
Clin Ther
|
2008
|
0.75
|
|
224
|
[The Fabry's Disease Cardiomyopathy as Differential Diagnosis of Acute Coronary Syndrome].
|
Dtsch Med Wochenschr
|
2017
|
0.75
|
|
225
|
The metabolic burden of diabetes and dyslipidaemia in chronic kidney disease.
|
Nephrol Dial Transplant
|
2002
|
0.75
|
|
226
|
[The diabetic patient with nephropathy].
|
MMW Fortschr Med
|
2014
|
0.75
|
|
227
|
The renal safety profile of fluvastatin: results of a pooled analysis.
|
Ren Fail
|
2006
|
0.75
|
|
228
|
Matching efficacy of online hemodiafiltration in simple hemodialysis mode.
|
Artif Organs
|
2008
|
0.75
|
|
229
|
Alternative approach for rapid and reliable single-nucleotide polymorphism typing with double restriction mutagenesis primer PCR.
|
Clin Chem
|
2004
|
0.75
|
|
230
|
Sympathomodulatory effects of sodium-glucose transporter-2 inhibitors in the kidneys and beyond.
|
J Hypertens
|
2017
|
0.75
|